|
Hepatitis, Toxic
|
0.300 |
Biomarker
|
disease |
CTD_human |
"Serum microRNA signatures as ""liquid biopsies"" for interrogating hepatotoxic mechanisms and liver pathogenesis in human."
|
28545106 |
2017 |
|
Drug-Induced Liver Disease
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
"Serum microRNA signatures as ""liquid biopsies"" for interrogating hepatotoxic mechanisms and liver pathogenesis in human."
|
28545106 |
2017 |
|
Hepatitis, Drug-Induced
|
0.300 |
Biomarker
|
disease |
CTD_human |
"Serum microRNA signatures as ""liquid biopsies"" for interrogating hepatotoxic mechanisms and liver pathogenesis in human."
|
28545106 |
2017 |
|
Drug-Induced Acute Liver Injury
|
0.300 |
Biomarker
|
disease |
CTD_human |
"Serum microRNA signatures as ""liquid biopsies"" for interrogating hepatotoxic mechanisms and liver pathogenesis in human."
|
28545106 |
2017 |
|
Chemical and Drug Induced Liver Injury
|
0.300 |
Biomarker
|
disease |
CTD_human |
"Serum microRNA signatures as ""liquid biopsies"" for interrogating hepatotoxic mechanisms and liver pathogenesis in human."
|
28545106 |
2017 |
|
Chemically-Induced Liver Toxicity
|
0.300 |
Biomarker
|
disease |
CTD_human |
"Serum microRNA signatures as ""liquid biopsies"" for interrogating hepatotoxic mechanisms and liver pathogenesis in human."
|
28545106 |
2017 |
|
Osteoporosis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
<b>Materials and methods:</b> The expression of miR-152 and RICTOR were tested in ovariectomized rat models of osteoporosis.
|
31492082 |
2019 |
|
LATERAL MENINGOCELE SYNDROME
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
59 primary STS samples (27 LMS and 32 UPS) and 10 matched normal control tissues were included in the study, as well as 3 STS-derived cell lines (HT1080, SW872 and SKLMS1) and a normal control mesenchymal cell line (hMSC). miRNA expression analyses were performed using a TaqMan microRNA Array platform and qRT-PCR (miR-152), respectively.
|
27900663 |
2017 |
|
LIMB-MAMMARY SYNDROME
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
59 primary STS samples (27 LMS and 32 UPS) and 10 matched normal control tissues were included in the study, as well as 3 STS-derived cell lines (HT1080, SW872 and SKLMS1) and a normal control mesenchymal cell line (hMSC). miRNA expression analyses were performed using a TaqMan microRNA Array platform and qRT-PCR (miR-152), respectively.
|
27900663 |
2017 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
miR-152 is involved in the genesis and development of several malignancies.
|
24998573 |
2014 |
|
Hepatitis B
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
miR-152 expression in HCC was downregulated remarkably compared to that in adjacent hepatic tissues. miR-152 levels in groups of advanced clinical stage, larger tumor size and positive HBV infection, were significantly lower than in other groups.
|
24998573 |
2014 |
|
Carcinoma of larynx
|
0.010 |
Biomarker
|
disease |
BEFREE |
MiR-152 may serve as a novel prognostic marker in patients with supragalottic laryngeal carcinoma.
|
25095980 |
2014 |
|
Rheumatoid Arthritis
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
MiR-152 and DNA methylation may provide molecular mechanisms for the activation of canonical Wnt pathway in RA.
|
25194984 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
MiR-152 was upregulated to the greatest extent and was also found to be upregulated by hypoxia in C33A cells and tumor, but not in non-tumor cervical tissues.
|
26515145 |
2016 |
|
Hepatocarcinogenesis
|
0.040 |
Biomarker
|
disease |
BEFREE |
MicroRNA-152-mediated dysregulation of hepatic transferrin receptor 1 in liver carcinogenesis.
|
26657500 |
2016 |
|
Malignant neoplasm of colon and/or rectum
|
0.020 |
Biomarker
|
disease |
BEFREE |
miR-152 functions as a tumor suppressor in colorectal cancer by targeting PIK3R3.
|
26820128 |
2016 |
|
leiomyosarcoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
miR-152 down-regulation is associated with MET up-regulation in leiomyosarcoma and undifferentiated pleomorphic sarcoma.
|
27900663 |
2017 |
|
Adult Leiomyosarcoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
miR-152 down-regulation is associated with MET up-regulation in leiomyosarcoma and undifferentiated pleomorphic sarcoma.
|
27900663 |
2017 |
|
Childhood Leiomyosarcoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
miR-152 down-regulation is associated with MET up-regulation in leiomyosarcoma and undifferentiated pleomorphic sarcoma.
|
27900663 |
2017 |
|
Adult Undifferentiated Pleomorphic Sarcoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
miR-152 down-regulation is associated with MET up-regulation in leiomyosarcoma and undifferentiated pleomorphic sarcoma.
|
27900663 |
2017 |
|
Malignant Fibrous Histiocytoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
miR-152 down-regulation is associated with MET up-regulation in leiomyosarcoma and undifferentiated pleomorphic sarcoma.
|
27900663 |
2017 |
|
Childhood Undifferentiated Pleomorphic Sarcoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
miR-152 down-regulation is associated with MET up-regulation in leiomyosarcoma and undifferentiated pleomorphic sarcoma.
|
27900663 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
MicroRNA-152 inhibits tumor cell growth by directly targeting RTKN in hepatocellular carcinoma.
|
27922690 |
2017 |
|
Liver carcinoma
|
0.090 |
Biomarker
|
disease |
BEFREE |
MicroRNA-152 inhibits tumor cell growth by directly targeting RTKN in hepatocellular carcinoma.
|
27922690 |
2017 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
MicroRNA‑152 inhibits cell proliferation, migration and invasion by directly targeting MAFB in nasopharyngeal carcinoma.
|
28000885 |
2017 |